Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis
Open Access
- 12 October 2026
- journal article
- other
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 178
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims dataJNCI: Journal of the National Cancer Institute, 2026
- Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health recordseClinicalMedicine, 2026
- Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patientsEuropean Journal of Pharmacology, 2025
- Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-AnalysisGastroenterology, 2025
- GLP-1-based therapies for diabetes, obesity and beyondNature Reviews Drug Discovery, 2025
- Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor AgonistsJAMA Network Open, 2025
- Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetesJNCI Cancer Spectrum, 2024
- Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesJACC, 2024
- Global burden of hematologic malignancies and evolution patterns over the past 30 yearsBlood Cancer Journal, 2023
- Obesity and risk of non‐Hodgkin's lymphoma: A meta‐analysisInternational Journal of Cancer, 2007